Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

Dendritic cells (DCs) are potent antigen-presenting cells that initiate protective T-cell immunity in mice. To study the immunogenicity of DCs in humans, we injected 9 healthy subjects subcutaneously with a control injection of autologous monocyte-derived, mature DCs, followed 4-6 weeks later by DCs pulsed with keyhole limpet hemocyanin (KLH), HLA-A*0201-positive restricted influenza matrix peptide (MP), and tetanus toxoid (TT). Four more subjects received these antigens without DCs. Injection of unpulsed DCs, or antigens alone, failed to immunize. Priming of CD4(+) T cells to KLH was observed in all 9 subjects injected with KLH-pulsed DCs, and boosting of TT-specific T-cell immunity was seen in 5 of 6 subjects injected with TT-pulsed DCs. Injection of antigen-pulsed DCs led to a severalfold increase in freshly isolated MP-specific, IFN-gamma-secreting CD8(+) T cells in all 6 HLA-A*0201-positive subjects, as early as 7 days after injection. When T cells were boosted in culture, there was an increase in MHC tetramer-binding cells and cytotoxic T cells after DC vaccination. These data provide the first controlled evidence of the immunogenicity of DCs in humans, and demonstrate that a single injection of mature DCs rapidly expands T-cell immunity.

[1]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[2]  S. Hoffman,et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.

[3]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[4]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[5]  F. Sallusto,et al.  Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.

[6]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[7]  J. Mayordomo,et al.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.

[8]  Seah H. Lim,et al.  Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  K. Rock,et al.  Fully mobilizing host defense: Building better vaccines , 1998, Nature Biotechnology.

[10]  R. Steinman,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.

[11]  R. Zinkernagel,et al.  Antiviral immunity. , 1997, Immunology today.

[12]  A. McMichael,et al.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.

[13]  R. Grant,et al.  Activity of a ritonavir plus saquinavir‐containing regimen in patients with virologic evidence of indinavir or ritonavir failure , 1998, AIDS.

[14]  L. Zitvogel,et al.  Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines , 1997, Stem cells.

[15]  Liangji Zhou,et al.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Harris,et al.  The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. , 1970, Clinical and experimental immunology.

[17]  M. Shapero,et al.  A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. , 1998, AIDS research and human retroviruses.

[18]  R. Steinman,et al.  Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. , 1996, Journal of immunological methods.

[19]  G. Murphy,et al.  Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen , 1996, The Prostate.

[20]  R. Siliciano,et al.  Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. , 1998, The Journal of infectious diseases.

[21]  R. Steinman,et al.  Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. , 1994, The Journal of clinical investigation.

[22]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[23]  W. Storkus,et al.  B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .

[24]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[25]  E. Gilboa,et al.  Induction of antitumor immunity using bone marrow-generated dendritic cells. , 1996, Journal of immunology.

[26]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[27]  G. Ogg,et al.  Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood , 1998, Current Biology.

[28]  N. Bhardwaj,et al.  A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. , 1997, Blood.

[29]  A. McMichael,et al.  Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.

[30]  R. Steinman,et al.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. , 1999, AIDS.

[31]  R. Steinman,et al.  Antigen presentation and related immunological aspects of HIV-1 vaccines. , 1998, AIDS.